

Szívelégtelenség

A megtartott ejekciós frakciójú szívelégtelenséggel (HFpEF) kapcsolatos tudományos publikációk

- Solomon S.D. et al . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction N Engl J Med 2022; 387:1089-1098 DOI: 10.1056/NEJMoa2206286
- Jhund PS et al Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER Nature Medicine volume 28, pages1956–1964 (2022)
- Vaduganathan M et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials The Lancet Volume 400, Issue 10354, 3 September 2022, Pages 757-767
- Vaduganathan M et al Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2022 Oct 3. doi: 10.1001/jamacardio.2022.3750. Online ahead of print. PMID: 36190011
- Desai AS et al. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Oct 3. doi: 10.1001/jamacardio.2022.3736. Online ahead of print. PMID: 36189985
- Peikert A. et al. Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial Originally published 27 Aug 2022 <https://doi.org/10.1161/CIRCHEARTFAILURE.122.010080> Circulation: Heart Failure. 2022;0
- Corbalan R, Acevedo M, Glifozins and Atrial Fibrillation, Journal of the American College of Cardiology (2022), doi: <https://doi.org/10.1016/j.jacc.2022.08.746>.
- Myhre PL et al. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction JACC: Heart Failure Available online 27 August 2022 <https://doi.org/10.1016/j.jchf.2022.08.007>
- Adamson C et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial, European Heart Journal, 2022;, ehac481, <https://doi.org/10.1093/eurheartj/ehac481>
- Butt et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial Originally published 27 Aug 2022 <https://doi.org/10.1161/CIRCULATIONAHA.122.061754> Circulation. 2022;0

- Cunningham J et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. null2022, 0 (0) .
<https://doi.org/10.1016/j.jacc.2022.07.021>
- Vaduganathan M et al. Estimated Event-Free Survival Benefits with Dapagliflozin in HF with Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. null2022, 0 (0) .
<https://doi.org/10.1016/j.jacc.2022.08.745>
- Butt J et al. Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. J Am Coll Cardiol. null2022, 0 (0) .
<https://doi.org/10.1016/j.jacc.2022.08.718>
- Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction (DELIVER baseline characteristics)
<https://www.jacc.org/doi/epdf/10.1016/j.jchf.2021.11.006>
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial (PRESERVED-HF trial)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604725/pdf/41591_2021_Article_1536.pdf
- A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202181/pdf/nihms970899.pdf>
- Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296715/pdf/1414-431X-bjmr-53-7-e9646.pdf>
- Ejection fraction in heart failure revisited where does the evidence start?
<https://academic.oup.com/eurheartj/article/41/25/2363/5827050?login=true>

DAPA HF vizsgálathoz kapcsolódó tudományos publikációk

- Murray et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607736/pdf/EJHF-21-665.pdf>
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF results)
<https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911303?articleTools=true>

- Martinez et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
<https://pubmed.ncbi.nlm.nih.gov/31736328/>
- Solomon et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
<https://pubmed.ncbi.nlm.nih.gov/32653447/>
- Jhund et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
<https://pubmed.ncbi.nlm.nih.gov/33040613/>
- Serenelli et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
<https://pubmed.ncbi.nlm.nih.gov/32820334/>
- McEwan et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF
<https://pubmed.ncbi.nlm.nih.gov/32749733/>
- Inzucchi et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
<https://doi.org/10.2337/dc20-1675>
- Yeoh et al. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
<https://pubmed.ncbi.nlm.nih.gov/33164553/>
- Kosiborod et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
<https://pubmed.ncbi.nlm.nih.gov/31736335/>
- Shen et al. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
<https://pubmed.ncbi.nlm.nih.gov/33549554/>
- Docherty et al. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
<https://pubmed.ncbi.nlm.nih.gov/32883108/>

Egyéb a kardiorenális és metabolikus betegségekkel kapcsolatos tudományos publikációk

- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE–TIMI 58)
<https://www.nejm.org/doi/full/10.1056/nejmoa1812389>
- Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
<https://www.nejm.org/doi/full/10.1056/NEJMoa2024816>
- Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
<https://pubmed.ncbi.nlm.nih.gov/34856173/>
- Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
<https://www.sciencedirect.com/science/article/pii/S2213177921003346>

- Direct cardiac effects of SGLT2 inhibitors
<https://pubmed.ncbi.nlm.nih.gov/35303888/>
- Gliflozins in the Management of Cardiovascular Disease
<https://pubmed.ncbi.nlm.nih.gov/35613023/>

Irányelvek

- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
<https://pubmed.ncbi.nlm.nih.gov/34447992/>
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
<https://pubmed.ncbi.nlm.nih.gov/35379503/>
- Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
<https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2206>
- A 2021-ben publikált új ESC-irányelv krónikus szívelégtelenség diagnózisára és kezelésére vonatkozó ajánlásai
https://cardiologia.hungarica.eu/wp-content/uploads/2022/06/CH_2022_2-majoros_zsuzsanna.pdf
- A szívelégtelenség kezelésének új európai irányelve – ESC 2021. Az SGLT2-gátló kezelés helye az evidenciák mentén
http://publicatio.bibl.u-szeged.hu/24649/1/Habon_2022.pdf